Nuclear magnetic resonance and high-performance liquid chromatography- nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 498-505

  Foxall, P J D ^a   Lenz, E M ^a   Lindon, J C ^a   Neild, G H ^b   Wilson, I D ^c   Nicholson, J K ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

1H nuclear magnetic resonance urinalysis; 31P nuclear magnetic resonance; High performance liquid chromatography nuclear magnetic resonance; Ifosfamide; Nephrotoxicity

Indexed keywords

IFOSFAMIDE; MESNA;

CANCER INHIBITION; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG METABOLISM; DRUG RETENTION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEAN RESIDENCE TIME; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IFOSFAMIDE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029810668     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00032     Document Type: Conference Paper

References (16)

1. Nicholson JK, Wilson ID. High resolution proton NMR spectroscopy of biological fluids. Prog NMR Spectroscopy 1989;21:449-501.
2. Anthony ML, Lindon JC, Beddell CR, Nicholson JK. Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from high resolution proton nuclear magnetic resonance spectra of urine. Mol Pharmacol 1994;46:199-211.
3. 1H-NMR: a new detector for liquid chromatography. Anal Chem 1984;56:747A-58A.
4. Laude DA Jr, Wilkins CL. Nuclear magnetic resonance for the on-line identification of liquid chromatography eluents. Trends Anal Chem 1986;5:230-5.
5. Spraul M, Hofmann M, Dvortsak P, Nicholson JK, Wilson ID. Liquid chromatography coupled with high-field proton NMR for profiling human urine for endogenous compounds and drug metabolites. J Pharm Biomed Anal 1992;8:601-5.
6. Spraul M, Hofmann M, Lindon JC, Nicholson JK, Wilson ID. Liquid chromatography coupled with high-field proton nuclear magnetic resonance spectroscopy: current status and future prospects. Anal Proc 1993;30:390-2.
7. Spraul M, Hofmann M, Dvortsak D, Nicholson JK, Wilson ID. High performance liquid chromatography coupled to high-field proton nuclear magnetic resonance spectroscopy: application to the urinary metabolites of ibuprofen. Anal Chem 1993;65:327-30.
8. Wilson ID, Nicholson JK, Hofmann M, Spraul M, Lindon JC. Investigation of the human metabolism of antipyrine using coupled liquid chromatography and nuclear magnetic resonance spectroscopy of urine. J Chromatogr 1993;617:324-8.
9. 19F HPLC-NMR. J Magn Reson Anal 1995;1:9-12.
10. Brade WP, Herdich K, Varini M. Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985;12:1-47.
11. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamideinduced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987;71:127-39.
12. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65:732-8.
13. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993; 11:173-90.
14. 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 1992;260:1133-44.
15. 2H NMR spectroscopic studies on the metabolism and biochemical effects of 2-bromoethanamine in the rat. Biochem Pharmacol 1995;49:1349-59.
16. 1H NMR spectroscopy to investigate the urinary excretion of flurbiprofen metabolites. J Pharm Biomed Anal 1993;11:1009-16.